These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [New thrombolytic agents in myocardial infarction]. Charbonnier B; Lang M; Brochier M Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222 [TBL] [Abstract][Full Text] [Related]
7. Evidence for a sustained fibrinolytic response to anisoylated plasminogen streptokinase activator complex in vitro. Fears R Drugs; 1987; 33 Suppl 3():83-7. PubMed ID: 3315617 [No Abstract] [Full Text] [Related]
8. Comparison of the effects of streptokinase, t-PA and APSAC on human platelet aggregation in vitro in the absence and presence of aspirin. Fears R; Ferres H; Greenwood HC Thromb Res; 1990 Nov; 60(4):259-68. PubMed ID: 2128420 [TBL] [Abstract][Full Text] [Related]
9. A comparison of acylated streptokinase-plasminogen complex and streptokinase in healthy volunteers. Prowse CV; Hornsey V; Ruckley CV; Boulton FE Thromb Haemost; 1982 Apr; 47(2):132-5. PubMed ID: 7048621 [TBL] [Abstract][Full Text] [Related]
10. Streptokinase and anisoylated streptokinase plasminogen complex. Their action on haemostasis in human volunteers. Staniforth DH; Smith RA; Hibbs M Eur J Clin Pharmacol; 1983; 24(6):751-6. PubMed ID: 6350023 [TBL] [Abstract][Full Text] [Related]
11. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. Massel D Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776 [TBL] [Abstract][Full Text] [Related]
12. Effect of epsilon-aminocaproyl-S-benzyl-L-cysteine on the activity of plasminogen activators. Bruzgo I; Midura-Nowaczek K; Kaczyńska J; Krajewska D Acta Pol Pharm; 2009; 66(1):37-40. PubMed ID: 19226966 [TBL] [Abstract][Full Text] [Related]
13. Development of novel thrombolytic agents. Collen D; De Bono DP; Lijnen HR; Pannekoek H J Intern Med; 1994 Oct; 236(4):433-7. PubMed ID: 7931045 [No Abstract] [Full Text] [Related]
14. On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921). Matsuo O; Collen D; Verstraete M Thromb Res; 1981 Nov; 24(4):347-58. PubMed ID: 7038976 [No Abstract] [Full Text] [Related]
15. Quality aspects of fibrinolytic agents based on biochemical characterization. Werner RG; Bassarab S; Hoffmann H; Schlüter M Arzneimittelforschung; 1991 Nov; 41(11):1196-200. PubMed ID: 1810268 [TBL] [Abstract][Full Text] [Related]
16. Consequences of antibody binding in vitro on the pharmacological properties of anisoylated plasminogen streptokinase activator complex. Fears R; Ferres H; Hibbs M; Standring R Drugs; 1987; 33 Suppl 3():64-8. PubMed ID: 3315614 [No Abstract] [Full Text] [Related]
17. [Behavior of postoperative adhesions after intraperitoneal administration of fibrinolytic drugs in a rat model]. Stapel A; Geissler N; Mlasowsky B; Jung D Langenbecks Arch Chir; 1997; 382(1):33-6. PubMed ID: 9157230 [TBL] [Abstract][Full Text] [Related]
18. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Gurewich V; Pannell R Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707 [No Abstract] [Full Text] [Related]